Cetuximab | 合法藥品大搜索

Cetuximabisanepidermalgrowthfactorreceptor(EGFR)inhibitormedicationusedforthe...KRAS,sinceithadlittleornoeffectincolorectaltumorsharboringaKRASmutation(thisalsoappliedtotheEGFRantibodypanitumumab).

Pharmaceutical drug

Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer.[2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion.[2]

In July 2009, the U.S. Food and Drug Administration (FDA) approved cetuximab (Erbitux) for treatment of colon cancer with wild-type KRAS, since it had little or no effect in colorectal tumors harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab).[4] This was the first genetic test to guide treatment of cancer.[5] In July 2012, the FDA approved a real time PCR companion diagnostic test for KRAS, the therascreen KRAS test.[6] In June 2024 together with adagrasib it was approved by the FDA for colorectal cancer.[7][8]

In the US, cetuximab is indicated for treatment of head and neck cancer and colorectal cancer.[2]

In the EU, cetuxi...